{
    "root": "34674732-e210-d135-e063-6294a90ac0ec",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "fluvoxamine maleate",
    "value": "20250505",
    "ingredients": [
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "STARCH, POTATO",
            "code": "8I089SAH3T"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FLUVOXAMINE MALEATE",
            "code": "5LGN83G74V"
        }
    ],
    "indications": "Fluvoxamine Maleate Tablets are indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD) ( 1 ).",
    "contraindications": "Adults: Recommended starting dose is 50 mg at bedtime, with increases of 50 mg every 4 to 7 days as tolerated to maximum effect, not to exceed 300 mg/day. Daily doses over 100 mg should be divided. ( 2.1 ). Children and adolescents (8 -17 years): Recommended starting dose is 25 mg at bedtime, with increases of 25 mg every 4 to 7 days as tolerated to maximum effect, not to exceed 200 mg/day (8 -11 years) or 300 mg/day (12 -17 years). Daily doses over 50 mg should be divided ( 2.2 ). Hepatically impaired: Decreased clearance may require modified dose and titration ( 2.3 ). Extended treatment: Adjust dose to maintain lowest effective dose; reassess patients periodically ( 2.6 ). Discontinuation: Gradual dose reduction is recommended ( 2.7 , 5.9 ).",
    "warningsAndPrecautions": "Fluvoxamine Maleate Tablets USP are available in the following strengths, colors, imprints, and presentations:\n                  Tablets 50 mg: scored, yellow, elliptical, film-coated (debossed “1225” on one side and scored on the other)\n                  NDC: 70518-1643-00\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Keep out of reach of children.\n                  Fluvoxamine Maleate Tablets should be protected from high humidity and stored at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].\n                  Dispense in tight containers.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Coadministration\n                  \n                  Coadministration of tizanidine, thioridazine, alosetron, or pimozide with Fluvoxamine Maleate Tablets is contraindicated\n \n  [see Warnings and Precautions (\n  \n   5.4,\n  \n   5.5,\n  \n   5.6,\n  \n   5.7)]\n \n  .\n\n \n                  \n                     Serotonin Syndrome and Monoamine Oxidase Inhibitors (MAOIs)\n                  \n                  The use of MAOIs intended to treat psychiatric disorders with Fluvoxamine Maleate Tablets or within 14 days of stopping treatment with Fluvoxamine Maleate Tablets is contraindicated because of an increased risk of serotonin syndrome. The use of Fluvoxamine Maleate Tablets within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated\n \n  [see Dosage and Administration (\n                     \n                        2.4\n                     \n                     ), Warnings and Precautions (\n  \n   5.2)]\n \n  .\n\n \n                  Starting Fluvoxamine Maleate Tablets in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome\n \n  [see Dosage and Administration (\n                     \n                        2.5\n                     \n                     ), Warnings and Precautions (\n  \n   5.2)]\n \n  ."
}